



February 19, 2024  
55205724

**Subject: Healthcare Resilience & Clinical Trials in Israel**

In light of recent events, we wanted to provide you with an update on the ongoing efforts to maintain healthcare resilience in Israel, particularly regarding clinical trials.

As our nation navigates through challenging times following the October 7th attack, our healthcare system has demonstrated remarkable resilience and adaptability. Despite the turmoil, we've managed to balance immediate responses to crises while ensuring the continuation of routine healthcare services, including clinical trials.

Clinical trials play a pivotal role in advancing medical innovation and improving patient outcomes. Even amidst crises, their importance cannot be overstated. Israel's commitment to clinical research was evident during the COVID-19 pandemic, where we continued routine trials utilizing decentralized methods that adhere to local regulations.

We want to emphasize that the Ministry of Health and Israeli healthcare organizations are committed to supporting ongoing trials as well as improving the authorization process and timelines of new trials, by issuing centralized decisions and commencing mutual recognitions between the institutional review boards, in addition to permitting the use of decentralized methods. Our priority remains ensuring patients' health and well-being as well as continuation of treatment in order to maintain a stable environment for research activities.

Your continued support is instrumental in sustaining our efforts. Together, we can ensure that patients have continued access to cutting-edge medical solutions and that our research community thrives.

Thank you for your attention to this matter, and we look forward to our continued collaboration.

Sincerely,

Dr. Catherine Ela  
Head of the Clinical Trials Department  
Ministry of Health, Israel